A new player has joined the battle against COVID-19. NeuTigers, a Princeton spin-off company, has teamed up with Rajant Corporation to develop CovidDeep, an AI-powered monitoring, and screening solution. The device combines artificial intelligence (AI) and biosensors to detect the different phases of COVID-19. It is currently in validation after a promising clinical trial.
In a recent study with San Matteo Hospital in Pavia, Italy, researchers demonstrated that CovidDeep’s efficient AI neural networks can differentiate between healthy participants (tested SARS-CoV-2 negative), asymptomatic (tested SARS-CoV-2 positive that can stay home), or even symptomatic (SARS-CoV-2 positive that needs hospitalization), using only a small field of clinical biometric data obtained non-intrusively from off-the-shelf, wearable medical sensors. Following further validation, the solution could help in triaging people for targeted viral and antibody testing, getting them to self-quarantine sooner and get treatment faster, reports Neutigers.
“CovidDeep does not require the presence of a nurse or physician during testing. It uses physiological signals extracted using commercially available devices and achieves high test accuracy. As a result, it provides a testing mechanism that is accurate, easily accessible to the public, and easy for individuals to use. Furthermore, this mechanism only requires a few minutes of data collection from an individual to perform inference,” says study co-author Professor Ignazio R. Marino MD, EVP Jefferson International Innovative Strategic Ventures, Thomas Jefferson University, and Jefferson Health.
CovidDeep can empower medical professionals and individuals by:
- Using data collected in a HIPAA/GDPR-compliant manner from medical sensors embedded in smartphones, smartwatches and/or wearables
- Applying a machine learning model to screen participants and classify them as healthy, asymptomatic, or symptomatic
- Delivering efficient screening methods for SARS-CoV-2/COVID-19 globally, so those in resource and supply-strained areas can concentrate on the most urgent cases
“Right now, our biggest question is, how can we return to an open society and a productive economy without risking the collapse of the healthcare system? The answer is through a scalable SARS-CoV-2/COVID-19 screening system, which we knew we could bring to life with Rajant as our partner,” says Adel Laoui, CEO and founder of NeuTigers. “This is an essential advancement in smart healthcare, but our work doesn’t stop there. This partnership with Rajant also enables us to strategically address issues across cybersecurity, edge computing, and other IoT use cases across multiple verticals.”
“When we think about an AI-powered future, a SARS-CoV-2/COVID-19 screening solution is just the beginning. Our partnership with NeuTigers enables state-of-the-art AI applications in the healthcare, construction, and transportation industries, among others,” says Robert Schena, CEO of Rajant. “We have a responsibility to apply our technology in ways that support the greater global good, and with NeuTigers, we’re poised to tackle the immediate challenges of AI without losing sight of the big picture.”